Dr. Ravi Salgia on Management Strategies for Acquired Resistance to Targeted Therapies, Single Focus or More Diffuse

Dr. Ravi Salgia on Management Strategies for Acquired Resistance to Targeted Therapies, Single Focus or More Diffuse

From: GRACEcast
0 0 7 years ago
00:00
01:44
Medicine, #acquired, #cancergrace, #chicago, #clinically, #egfr, #grace, #gracecast, #indolent, #inhibitor, #metastasis, #of, #oligoprogression, #progression, #ravi, #resistance, #significant, #solitary, #t790m, #tki, #university
Dr. Ravi Salgia from University of Chicago explains his approach to management of acquired resistance to a targeted therapy for advanced NSCLC, both in the setting of a single area of progression and also when disease progression is more diffuse.

Author

cancerGRACE Meetings
cancerGRACE Meetings 2 followers Follow

Find us on Facebook

Spreaker logo
  • Choose Language

For Podcasters and Editors

Tools for Podcasters

For Listeners

Copyright 2021 - Spreaker Inc. a Voxnest Company - Create a Podcast - New York, NY